Work at Zhuhai United Laboratories Co. Ltd. has led to the identification of new apelin receptor (APLNR) agonists reported to be useful for the treatment of diabetes, heart failure, muscle atrophy, chronic kidney disease, pulmonary hypertension, amyotrophic lateral sclerosis, atherosclerosis and Alzheimer’s disease, among others.
A joint Nankai University and Tianjin Accendatech Technology Co. Ltd. patent describes new isoalantolactone derivatives reported to be useful for the treatment of liver cancer.
A team at the Korea Research Institute of Chemical Technology has synthesized tetrahydroisoquinoline- or isoindoline-substituted [1,2,4]triazolo[1,5-a]pyridine derivatives acting as tyrosine-protein kinase JAK1 inhibitors.
Solve Therapeutics Inc. has prepared and tested new antibody-drug conjugates (ADCs) comprising a monoclonal antibody targeting trophoblast glycoprotein (TPBG; 5T4) covalently linked to cytotoxic drug and reported to be useful for the treatment of cancer.
Yuanyi Wise Tech (Ningbo) Ltd. has prepared and tested new tricyclic compounds acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12V mutant) interaction inhibitors potentially useful for the treatment of cancer.
Agomab Therapeutics NV has identified new TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors designed for use in the treatment of idiopathic pulmonary fibrosis.
Deepcure Inc. has synthesized new 3,4-dihydroquinoxalin-2(1H)-ones acting as bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors. As such, they are described as potentially useful for the treatment of autoimmune, cardiovascular disease, inflammatory disorders, multiple sclerosis, psoriasis, gout, obesity, and sepsis, among others.
Genosco Inc. has patented new molecular glue degraders comprising cereblon-binding agents acting as GSPT and/or Myc proto-oncogene protein (c-Myc) degradation inducers designed for use in the treatment of cancer.
RSS